Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Zanubrutinib maintained a PFS benefit at 5 years vs benadmustine and rituximab for patients with CLL/SLL.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

For patients with acute lymphoblastic leukemia and mantle cell leukemia, lymphodepletion then brexu-cel show positive efficacy and safety outcomes.